GlassScriptPhysician profile
Baljinder Singh
NPI 1356539415
$78,933.13
in general payments reported to CMS, 2019-2025
69 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $15K · 2021: $15K · 2022: $13K · 2023: $11K · 2024: $13K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $1,688 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,664.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,250.00 |
| Travel and Lodging | $1,688.24 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36,201.78 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $15,648.98 | 2020-2022 | |
| Livanova USA, INC. | $2,844.52 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Abbott Laboratories | $2,539.25 | 2022-2025 | Infinity, Octrode, Jot Dx |
| Ucb, INC. | $2,211.92 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $1,608.47 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tg Therapeutics, INC. | $1,366.47 | 2023-2025 | |
| Biogen, INC. | $1,256.98 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Sk Life Science, INC. | $1,094.95 | 2021-2025 | Xcopri |
| Pfizer INC. | $947.89 | 2020-2025 | |
| Amgen INC. | $755.13 | 2020-2025 | Uplizna, Aimovig |
| Celgene Corporation | $659.88 | 2020-2025 | Zeposia |
| Lilly USA, LLC | $648.38 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Emd Serono, INC. | $633.65 | 2020-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $612.55 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $562.41 | 2019-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $552.12 | 2020-2023 | Invega Sustenna |
| Mdd US Operations, LLC | $516.04 | 2019-2025 | Gocovri |
| Alexion Pharmaceuticals, INC. | $506.08 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $483.71 | 2019-2025 | |
| Boston Scientific Corporation | $464.40 | 2019-2025 | Watchman Flx, Vercise, Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $454.05 | 2023-2025 | Rexulti |
| Neurelis, INC. | $435.08 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $387.08 | 2019-2025 | Qelbree |
| Amneal Pharmaceuticals LLC | $381.91 | 2021-2025 | Crexont, Rytary |
| Eisai INC. | $350.56 | 2022-2025 | |
| Argenx US, INC. | $309.11 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $263.78 | 2021-2024 | Amvuttra, Onpattro |
| Lundbeck LLC | $257.95 | 2019-2025 | Rexulti, Vyepti |
| Janssen Biotech, INC. | $253.61 | 2025 | |
| Upsher-Smith Laboratories LLC | $236.31 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $223.70 | 2021 | |
| Vanda Pharmaceuticals INC. | $222.79 | 2021-2025 | Ponvory, Hetlioz |
| Ge Healthcare | $222.05 | 2019-2024 | |
| Kyowa Kirin, INC. | $194.66 | 2021-2023 | Nourianz |
| Grifols USA, LLC | $187.47 | 2020-2025 | Gamunex-C |
| Sunovion Pharmaceuticals INC. | $166.14 | 2019-2022 | |
| Axsome Therapeutics, INC. | $163.75 | 2025 | Symbravo |
| Impel Pharmaceuticals INC. | $163.43 | 2022-2023 | Trudhesa |
| E.R. Squibb & Sons, L.L.C. | $161.01 | 2019-2024 | Camzyos, Eliquis |
| Acorda Therapeutics, INC | $150.16 | 2021-2023 | Inbrija, Ampyra |
| Genzyme Corporation | $147.95 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.34 | 2019-2025 | Hyqvia, Trintellix |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $106.51 | 2022-2024 | Keveyis |
| Banner Life Sciences, LLC | $106.14 | 2022 | |
| Esperion Therapeutics, INC. | $103.14 | 2021 | |
| Tanabe Pharma America, INC. | $90.78 | 2023-2025 | Radicava |
| Scilex Pharmaceuticals INC. | $74.04 | 2021-2025 | Ztlido |
| Merz Pharmaceuticals, LLC | $66.39 | 2025 | Inbrija, Xeomin |
| Averitas Pharma INC. | $64.46 | 2024-2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $57.87 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $55.80 | 2021 | |
| Horizon Therapeutics Plc | $49.80 | 2022-2023 | Uplizna |
| Cycle Pharmaceuticals INC | $44.25 | 2024-2025 | Tascenso Odt, Bafiertam |
| Catalyst Pharmaceuticals, INC. | $39.96 | 2024 | |
| Collegium Pharmaceutical, INC. | $33.74 | 2022 | |
| Acadia Pharmaceuticals INC | $23.64 | 2019-2021 | |
| Csl Behring | $23.04 | 2023 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.04 | 2020 | |
| Exact Sciences Corporation | $22.56 | 2023 | Cologuard Collection Kit |
| Phadia US INC. | $21.63 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.00 | 2024 | Voquezna |
| Aucta Pharmaceuticals, INC. | $19.98 | 2025 | Motpoly Xr |
| Sumitomo Pharma America, INC. | $15.25 | 2023 | Aptiom |
| Amarin Pharma, INC. | $14.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2023 | Seglentis |
| Metacel Pharmaceuticals LLC | $7.93 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baljinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.